RÃ©gis Bordet

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9056171/publications.pdf

Version: 2024-02-01

70 papers	2,274 citations	257450 24 h-index	243625 44 g-index
74 all docs	74 docs citations	74 times ranked	4172 citing authors

#	Article	IF	Citations
1	Biomarkers in the Prediction of Hemorrhagic Transformation in Acute Stroke: A Systematic Review and Meta-Analysis. Cerebrovascular Diseases, 2022, 51, 235-247.	1.7	18
2	Effects of acute ethanol and/or diazepam exposure on immediate and delayed hippocampal metabolite levels in rats anesthetized with isoflurane. Fundamental and Clinical Pharmacology, 2022, 36, 687-698.	1.9	1
3	Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimerâ€™s disease CSF profile of neuronal injury and inflammation. Molecular Psychiatry, 2022, 27, 1990-1999.	7.9	9
4	Long-term cognitive impairments following COVID-19: a possible impact of hypoxia. Journal of Neurology, 2022, 269, 3982-3989.	3.6	19
5	Genome-Wide Association Study of Alzheimerâ€™s Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimerâ€™s Disease Multimodal Biomarker Discovery Dataset. Frontiers in Aging Neuroscience, 2022, 14, 840651.	3.4	20
6	Myeloneuropathy induced by recreational nitrous oxide use with variable exposure levels. European Journal of Neurology, 2022, 29, 2173-2180.	3.3	14
7	Texture Features of Magnetic Resonance Images Predict Poststroke Cognitive Impairment: Validation in a Multicenter Study. Stroke, 2022, 53, 3446-3454.	2.0	2
8	Age and diet modify acute microhemorrhage outcome in the mouse brain. Neurobiology of Aging, 2021, 98, 99-107.	3.1	1
9	Accuracy and reproducibility of automated white matter hyperintensities segmentation with lesion segmentation tool: A European multi-site 3T study. Magnetic Resonance Imaging, 2021, 76, 108-115.	1.8	24
10	Towards personalized pharmacology: Antipsychotics and schizophrenia. Therapie, 2021, 76, 137-147.	1.0	3
11	Early epileptic seizures in ischaemic stroke treated by mechanical thrombectomy: influence of rt-PA. Journal of Neurology, 2021, 268, 305-311.	3.6	5
12	Prediction of Long-term Cognitive Function After Minor Stroke Using Functional Connectivity. Neurology, 2021, 96, .	1.1	19
13	Contributions of animal models of cognitive disorders to neuropsychopharmacology. Therapie, 2021, 76, 87-99.	1.0	2
14	Beneficial effects of atorvastatin on sexâ€specific cognitive impairment induced by a cerebral microhaemorrhage in mice. British Journal of Pharmacology, 2021, 178, 1705-1721.	5.4	3
15	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. Alzheimer's and Dementia, 2021, 17, 1628-1640.	0.8	23
16	Functional connectivity and cognitive changes after donepezil treatment in healthy participants. Psychopharmacology, 2021, 238, 3071-3082.	3.1	5
17	Warning on increased serious health complications related to non-medical use of nitrous oxide. Therapie, 2021, 76, 478-479.	1.0	10
18	Sex Differences in Cognitive Impairment Induced by Cerebral Microhemorrhage. Translational Stroke Research, 2021, 12, 316-330.	4.2	8

#	Article	IF	Citations
19	Sex-Specific Metabolic Pathways Were Associated with Alzheimerâ€™s Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. Biomedicines, 2021, 9, 1610.	3.2	7
20	Lack of direct involvement of a diazepam long-term treatment in the occurrence of irreversible cognitive impairment: a pre-clinical approach. Translational Psychiatry, 2021, 11, 612.	4.8	5
21	Antihypertensive agents in Alzheimerâ€™s disease: beyond vascular protection. Expert Review of Neurotherapeutics, 2020, 20, 175-187.	2.8	26
22	Mechanism of action of s1p receptor modulators in multiple sclerosis: The double requirement. Revue Neurologique, 2020, 176, 100-112.	1.5	11
23	Remote brain hemorrhage after IV thrombolysis. Neurology, 2020, 94, e961-e967.	1.1	14
24	Genome-wide association study of Alzheimerâ€™s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. Translational Psychiatry, 2020, 10, 403.	4.8	42
25	Brainâ€“liver axis: a new pathway for cognitive disorders related to hepatic fibrosis. European Journal of Neurology, 2020, 27, 2111-2112.	3.3	12
26	Is the drug a scientific, social or political object?. Therapie, 2020, 75, 389-391.	1.0	8
27	Analysis of the association of MPO and MMP-9 with stroke severity and outcome. Neurology, 2020, 95, e97-e108.	1.1	42
28	Drug interactions with dementiaâ€related pathophysiological pathways worsen or prevent dementia. British Journal of Pharmacology, 2019, 176, 3413-3434.	5.4	9
29	Safety of oral anticoagulants on experimental brain microbleeding and cognition. Neuropharmacology, 2019, 155, 162-172.	4.1	12
30	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. Alzheimer's and Dementia, 2019, 15, 817-827.	0.8	62
31	Profile of and risk factors for poststroke cognitive impairment in diverse ethnoregional groups. Neurology, 2019, 93, e2257-e2271.	1.1	117
32	A metaboliteâ€based machine learning approach to diagnose Alzheimerâ€type dementia in blood: Results from the European Medicalâ€‰Information Framework for Alzheimer disease biomarker discovery cohort. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 933-938.	3.7	70
33	Neutrophils in tPA-induced hemorrhagic transformations: Main culprit, accomplice or innocent bystander?. , 2019, 194, 73-83.		13
34	Biological and imaging predictors of cognitive impairment after stroke: a systematic review. Journal of Neurology, 2019, 266, 2593-2604.	3.6	38
35	Role of cortical microbleeds in cognitive impairment: InÂvivo behavioral and imaging characterization of a novel murine model. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 1015-1025.	4.3	9
36	IschÃ©mie cÃ©rÃ©braleÂ: la fin de la fatalitÃ©Â?. Bulletin De L'Academie Nationale De Medecine, 2019, 203, 144-153.	0.0	0

#	Article	IF	Citations
37	Identification of a specific functional network altered in poststroke cognitive impairment. Neurology, 2018, 90, e1879-e1888.	1.1	23
38	Hippocampal Deformations and Entorhinal Cortex Atrophy as an Anatomical Signature of Long-Term Cognitive Impairment: from the MCAO Rat Model to the Stroke Patient. Translational Stroke Research, 2018, 9, 294-305.	4.2	18
39	MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. Alzheimer's Research and Therapy, 2018, 10, 100.	6.2	64
40	Early MoCA predicts long-term cognitive and functional outcome and mortality after stroke. Neurology, 2018, 91, e1838-e1850.	1.1	119
41	Ongoing Electroencephalographic Activity Associated with Cortical Arousal in Transgenic PDAPP Mice (hAPP V717F). Current Alzheimer Research, 2018, 15, 259-272.	1.4	8
42	Are the results of intravenous thrombolysis trials reproduced in clinical practice? Comparison of observed and expected outcomes with the stroke-thrombolytic predictive instrument (STPI). Revue Neurologique, 2017, 173, 381-387.	1.5	13
43	Influence of Medication on Fatigue Six Months after Stroke. Stroke Research and Treatment, 2016, 2016, 1-9.	0.8	13
44	Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a â€˜European <scp>ADNI</scp> studyâ€™. Journal of Internal Medicine, 2016, 279, 576-591.	6.0	64
45	Orolingual Angioedema During or After Thrombolysis for Cerebral Ischemia. Stroke, 2016, 47, 1825-1830.	2.0	54
46	METACOHORTS for the study of vascular disease and its contribution to cognitive decline and neurodegeneration: An initiative of the Joint Programme for Neurodegenerative Disease Research. Alzheimer's and Dementia, 2016, 12, 1235-1249.	0.8	82
47	Proportion of single-chain recombinant tissue plasminogen activator and outcome after stroke. Neurology, 2016, 87, 2416-2426.	1.1	12
48	Blood biomarkers in the early stage of cerebral ischemia. Revue Neurologique, 2016, 172, 198-219.	1.5	31
49	Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinsonâ€™s Disease Stages?. PLoS ONE, 2016, 11, e0147947.	2.5	71
50	The role of PPAR activation during the systemic response to brain injury. Journal of Neuroinflammation, 2015, 12, 99.	7.2	21
51	Early treatment with atorvastatin exerts parenchymal and vascular protective effects in experimental cerebral ischaemia. British Journal of Pharmacology, 2015, 172, 5188-5198.	5.4	31
52	Factors Associated with Poststroke Fatigue: A Systematic Review. Stroke Research and Treatment, 2015, 2015, 1-11.	0.8	64
53	Which factors influence the resort to surrogate consent in stroke trials, and what are the patient outcomes in this context?. BMC Medical Ethics, 2015, 16, 26.	2.4	7
54	Transcranial magnetic stimulation and aging: Effects on spatial learning and memory after sleep deprivation in Octodon degus. Neurobiology of Learning and Memory, 2015, 125, 274-281.	1.9	10

#	Article	IF	Citations
55	Cognitive Impairment After Sleep Deprivation Rescued by Transcranial Magnetic Stimulation Application in Octodon degus. Neurotoxicity Research, 2015, 28, 361-371.	2.7	15
56	Higher neutrophil counts before thrombolysis for cerebral ischemia predict worse outcomes. Neurology, 2015, 85, 1408-1416.	1.1	165
57	Pharmacology of Hallucinations: Several Mechanisms for One Single Symptom?. BioMed Research International, 2014, 2014, 1-9.	1.9	64
58	Stroke-Induced Brain Parenchymal Injury Drives Bloodâ€“Brain Barrier Early Leakage Kinetics: A Combined in Vivo/in Vitro Study. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 95-107.	4.3	53
59	Baclofen-Induced Manic Symptoms: Case Report and Systematic Review. Psychosomatics, 2014, 55, 326-332.	2.5	41
60	The role of hemorrhage following spinal-cord injury. Brain Research, 2014, 1569, 9-18.	2.2	43
61	Influence of cognitive impairment on the management of ischaemic stroke. Revue Neurologique, 2014, 170, 177-186.	1.5	4
62	Post-mortem 7.0-tesla magnetic resonance study of cortical microinfarcts in neurodegenerative diseases and vascular dementia with neuropathological correlates. Journal of the Neurological Sciences, 2014, 346, 85-89.	0.6	46
63	Thrombolytic therapy for stroke in patients with preexisting cognitive impairment. Neurology, 2014, 82, 2048-2054.	1.1	20
64	Memantine prevents reference and working memory impairment caused by sleep deprivation in both young and aged Octodon degus. Neuropharmacology, 2014, 85, 206-214.	4.1	21
65	A very early neurological improvement after intravenous thrombolysis for acute cerebral ischaemia does not necessarily predict a favourable outcome. Acta Neurologica Belgica, 2013, 113, 67-72.	1.1	3
66	PPARs: A Potential Target for a Disease-Modifying Strategy in Stroke. Current Drug Targets, 2013, 14, 752-767.	2.1	23
67	Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Review of Neurotherapeutics, 2009, 9, 1413-1431.	2.8	120
68	Medical Pharmacology: From Review to Planning. Therapie, 2006, 61, 457-461.	1.0	2
69	PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochemical Society Transactions, 2006, 34, 1341-1346.	3.4	263
70	Stroke prevention: Management of modifiable vascular risk factors. Journal of Neurology, 2003, 250, 1125-1126.	3.6	1